A $4 million jury award is modest beside the multibillion-dollar valuations common in biotechnology. The implications of the Biohaven and Yale University verdict could be much larger.

Biohaven and Yale said on July 27 that a federal jury in Delaware found Avilar Therapeutics and RA Capital Management willfully and maliciously misappropriated a Yale trade secret related to the university’s MODA targeted protein degradation platform. The jury also found that RA Capital breached a 2019 confidentiality agreement with Yale.

The damages included $2 million to Yale for breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. The verdict was returned on July 24 after a trial that began four days earlier.

The case puts an uncomfortable spotlight on a routine part of biotech company formation: an academic inventor shares confidential science with a specialist investor, licensing talks end without a deal, and the investor later backs a company working in a related field.

From university pitch to competing platform

According to the account released by Biohaven and Yale, Yale professor David Spiegel developed the MODA platform to bind and eliminate disease-causing extracellular proteins. He presented the technology at Yale’s Lifesciences Pitchfest in 2018.

RA Capital entered a confidentiality agreement with Yale in April 2019 while evaluating a possible investment and partnership. Spiegel then shared technical information during negotiations. Those discussions ended without an agreement in August 2019.

Biohaven and Yale alleged that RA Capital and Avilar, which RA Capital helped establish later that year, used confidential information from the discussions to build a competing development program. Biohaven subsequently licensed the MODA platform from Yale. The plaintiffs filed suit in March 2023.

The jury’s finding of willful and malicious conduct is more significant than a simple disagreement over overlapping scientific concepts. It indicates that jurors accepted the argument that protected information was improperly used, and that the conduct went beyond accidental similarity.

Why the case matters to venture creation

Specialist life sciences investors do more than supply money. Many help identify academic discoveries, recruit management teams, shape development plans, and create new companies around emerging modalities. That model depends on investors seeing highly sensitive information before deciding whether to fund or license a technology.

Universities also need those discussions. Technology transfer offices rarely have the capital or operating capacity to develop every promising discovery themselves. They rely on investors and industry partners to evaluate opportunities and move selected programs toward patients.

The system works only if both sides trust the rules around confidential information. If academic teams believe an unsuccessful pitch could help seed a competing company, they may disclose less, delay discussions, or demand more restrictive diligence processes. That would make it harder for investors to assess opportunities and slower for universities to commercialise research.

The verdict therefore has practical implications for how venture firms document deal review. Firms that examine multiple technologies in the same modality need clear information barriers, disciplined record keeping, conflict checks, and written processes showing which ideas came from public sources, internal work, or confidential disclosures.

The damages do not measure the whole risk

The $4 million award may appear small relative to the cost of developing a biotechnology platform. But litigation exposure is only one consequence. Trade secret disputes can interrupt fundraising, complicate partnerships, consume management attention, create discovery obligations, and raise questions during acquisition diligence.

Reputational risk may be more consequential than damages for an investor whose business depends on founders and universities sharing their best ideas. A finding involving willful misuse can influence future counterparties even if the financial award is manageable.

The case also illustrates why confidentiality agreements are not boilerplate. Their definitions, permitted uses, residual knowledge provisions, disclosure limits, and dispute mechanisms can determine what happens years after a meeting that initially looked unsuccessful.

What happens next

The July 27 announcement presents the plaintiffs’ account of the case and verdict. Post-trial motions or appeals could follow, and the ultimate legal outcome may change. The defendants’ full position and any further court rulings will be important to the final interpretation.

For the biotechnology sector, however, the immediate lesson does not depend on the size of the award. The venture creation model requires investors to move rapidly across adjacent scientific opportunities. Speed does not reduce the need for provenance.

Every platform company needs a defensible record of where its foundational ideas, experiments, and development concepts originated. Every investor participating in company creation needs processes strong enough to distinguish pattern recognition from the use of protected information.

Biotech’s deal rooms run on confidential science. The Biohaven verdict is a reminder that trust in those rooms is an operating asset, and losing it can become a legal liability.